Retatrutide Research Compound 40mg Vial is a research-focused peptide compound presented in a 40mg vial format for laboratory and scientific research.

Retatrutide, also identified as LY3437943, is an investigational single-molecule triple hormone receptor agonist that activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. It is currently being investigated in clinical research programmes, making its molecular characteristics and receptor activity an ongoing area of scientific interest.

For research applications, retatrutide provides an area of interest for researchers examining peptide chemistry, molecular characterisation, analytical methods and formulation-related considerations. The compound’s multi-receptor profile also makes it relevant to broader research into peptide-based molecular systems.

The Retatrutide Research Compound 40mg Vial is presented within the AlluviLabsUK research catalogue with an emphasis on clear product identification, structured scientific information and research-focused documentation.

Product Information

Product: Retatrutide Research Compound 40mg Vial
Compound: Retatrutide
Research identifier: LY3437943
Stated quantity: 40mg
Format: Vial
Category: Research Peptide / Research Compound
Research areas: Peptide chemistry, molecular research, analytical research and formulation research
Brand: AlluviLabsUK

Research Use Only

This product is presented for legitimate research and laboratory purposes only. It is not intended for human or veterinary use, administration, diagnosis, treatment, cure or prevention of any disease. Retatrutide is an investigational compound and has not been approved for general public use.

Research Resources

Retatrutide Research Compound 40mg Vial